On July 6, 2025, a multicenter, randomized, double-blind, positive drug parallel controlled, non inferiority clinical trial to evaluate the efficacy and safety of inhaled beclomethasone dipropionate in the treatment of adult bronchial asthma, initiated by Leecan Pharmaceutical, was successfully held in Nanjing. The founder and chairman of Leecan Pharmaceutical attended the meeting and fully participated in the discussion.

The clinical trial leader, Professor Lin Jiangtao of China-Japan Friendship Hospital, and more than 50 clinical GCP、 Ethical experts, as well as representatives from Leecan Pharmaceutical Research Institute and collaborating CROs, attended the meeting. The purpose of this meeting is to conduct in-depth discussions on key issues related to the Phase III clinical trial of beclomethasone dipropionate inhalation aerosol, in order to build consensus and lay a solid foundation for the high-quality development of the project.

     In the opening speech, the founder and chairman of Leecan Pharmaceutical warmly welcomed Professor Lin Jiangtao and the attending experts. He introduced the entrepreneurial intention, development process, and series of products of Leecan Pharmaceutical. Since its inception, Leecan Pharmaceutical has "targeted" high-end inhalation preparations, a track with high barriers and intensive pain points, and is determined to break the monopoly and become China's own high-end inhalation preparations. Since its establishment in May 2021, Leecan Pharmaceutical has achieved the approval and listing of 5 inhalation formulation products in just four years, and 8 product specifications have been submitted for production and pending approval. The inhalation aerosol of beclomethasone dipropionate is a key product of Leecan Pharmaceutical's series and the first product to be promoted to phase III clinical trials. Leecan Pharmaceutical has overcome the difficulties related to pharmaceutical research and device research, but there are still many challenges in its clinical research. He hopes that today's discussion will bring together experts from multiple disciplines and fields to brainstorm and collide their wisdom, creating a clinical trial plan that can withstand scrutiny, striving to make this clinical trial a benchmark in the industry, and contributing to the improvement of the quality and level of clinical research on high-end inhalation preparations.

     During the seminar, the founder and chairman of Leecan Pharmaceutical, along with experts such as Professor Lin Jiangtao, conducted in-depth discussions on core topics such as research objectives, applicable populations, and treatment plans. They fully demonstrated the technical details and implementation steps of the experimental plan, ensuring that all parties involved in the study accurately understood the experimental plan and strictly carried out relevant work in accordance with the plan and GCP specifications.

     At the closing ceremony, the founder and chairman of Leecan Pharmaceutical expressed sincere gratitude to the experts for their valuable opinions. As the research and development manufacturer and clinical trial sponsor of this product, we will fully digest and absorb the results of this conference, provide key basis for the product's application for market launch with scientific, rigorous, and reliable clinical research results, and ultimately provide patients with safer, more reliable, and effective treatment options.